This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Benes, V. Articles by Spetzler, R. F. Search for Related Content PubMed PubMed Citation Articles by Benes, V. Articles by Spetzler, R. F. Pubmed/NCBI databases Substance via MeSH

Stroke, Vol 21, 1594-1599, Copyright © 1990 by American Heart Association

ARTICLES

Effect of intra-arterial tissue plasminogen activator and urokinase on autologous arterial emboli in the cerebral circulation of rabbits [corrected] [published erratum appears in Stroke 1991 Feb;22(2):285]

V Benes, JM Zabramski, M Boston, A Puca and RF Spetzler
Division of Neurological Surgery, Barrow Neurological Institute, Phoenix, AZ 85013-4496.

We conducted a randomized, blinded controlled trial to test the efficacy of fibrinolytic therapy with tissue plasminogen activator and urokinase in the treatment of acute embolic stroke. Embolic stroke was simulated in rabbits by injecting three 0.5 x 0.5 mm fragments of autologous arterial thrombus harvested from a traumatized auricular artery. Thirty minutes after embolization the rabbits were blindly treated with tissue plasminogen activator (n = 21), urokinase (n = 20), or 0.9% saline (n = 20). At 6 hours the rabbits were sacrificed, and the cerebral vasculature was inspected for the location and number of emboli. The brain was then cut into 0.5-cm-thick coronal sections and stained with triphenyltetrazolium chloride to define areas of infarction. Treatment with either tissue plasminogen activator or urokinase significantly reduced the number of emboli present in the cerebral circulation (p less than 0.05). The area of ischemic injury was also significantly reduced (p less than 0.05) by acute fibrinolytic therapy with either tissue plasminogen activator or urokinase. However, only treatment with tissue plasminogen activator significantly reduced (p less than 0.05) the incidence of infarction. There was no evidence of intracerebral hemorrhage in any rabbit. Early fibrinolytic therapy improved outcome in this model of acute embolic stroke.

This article has been cited by other articles:

				K. Kirchhof, T. Welzel, S. Zoubaa, C. Lichy, M. Sikinger, H. L. de Ruiz, and K. Sartor New Method of Embolus Preparation for Standardized Embolic Stroke in Rabbits Stroke, September 1, 2002; 33(9): 2329 - 2333. [Abstract] [Full Text] [PDF]

				T. F. Choudhri, B. L. Hoh, R. A. Solomon, E. S. Connolly Jr, and D. J. Pinsky Use of a Spectrophotometric Hemoglobin Assay to Objectively Quantify Intracerebral Hemorrhage in Mice Stroke, November 1, 1997; 28(11): 2296 - 2302. [Abstract] [Full Text]

				S. Vanderschueren, I. Van Vlaenderen, and D. Collen Intravenous Thrombolysis With Recombinant Staphylokinase Versus Tissue-Type Plasminogen Activator in a Rabbit Embolic Stroke Model Stroke, September 1, 1997; 28(9): 1783 - 1788. [Abstract] [Full Text]